Organogenesis Holdings Inc. financial data

Symbol
ORGO on Nasdaq
Industry
Pharmaceutical Preparations
Location
85 Dan Road, Canton, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Avista Healthcare Public Acquisition Corp. (to 12/10/2018)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 276 % -2.31%
Quick Ratio 33.5 % +4.75%
Debt-to-equity 66.3 % -6.08%
Return On Equity -6.03 % -259%
Return On Assets -3.63 % -263%
Operating Margin -2.44 % -169%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 133M shares +0.96%
Common Stock, Shares, Outstanding 133M shares +0.96%
Entity Public Float 236M USD -31.7%
Common Stock, Value, Issued 13K USD 0%
Weighted Average Number of Shares Outstanding, Basic 133M shares +0.98%
Weighted Average Number of Shares Outstanding, Diluted 133M shares -0.37%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 448M USD -1.96%
Cost of Revenue 111M USD +4.94%
Research and Development Expense 50.6M USD +17.5%
Operating Income (Loss) -11M USD -168%
Nonoperating Income (Expense) -2.08M USD -20.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -13M USD -190%
Income Tax Expense (Benefit) 3.5M USD -21.7%
Net Income (Loss) Attributable to Parent -16.5M USD -265%
Earnings Per Share, Basic -0.13 USD/shares -263%
Earnings Per Share, Diluted -0.13 USD/shares -263%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 89.9M USD +1.11%
Accounts Receivable, after Allowance for Credit Loss, Current 106M USD +13.2%
Inventory, Net 26.9M USD +5.99%
Assets, Current 234M USD +8.21%
Deferred Income Tax Assets, Net 33.7M USD +12.3%
Property, Plant and Equipment, Net 89.9M USD -19.6%
Operating Lease, Right-of-Use Asset 36.6M USD -16%
Intangible Assets, Net (Excluding Goodwill) 14.1M USD -22.9%
Goodwill 28.8M USD 0%
Other Assets, Noncurrent 5.85M USD +320%
Assets 443M USD -1.59%
Accounts Payable, Current 29.4M USD +7.3%
Employee-related Liabilities, Current 19.3M USD -0.62%
Accrued Liabilities, Current 38M USD +36.8%
Liabilities, Current 85.7M USD +16.7%
Operating Lease, Liability, Noncurrent 23.5M USD -42%
Other Liabilities, Noncurrent 1.27M USD +6.56%
Liabilities 180M USD +0.35%
Retained Earnings (Accumulated Deficit) -60.1M USD -38%
Stockholders' Equity Attributable to Parent 264M USD -2.87%
Liabilities and Equity 443M USD -1.59%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.2M USD -100%
Net Cash Provided by (Used in) Financing Activities -2.61M USD -111%
Net Cash Provided by (Used in) Investing Activities -2.22M USD +70.6%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 133M shares +0.96%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -15M USD -8.05%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 90.5M USD +1.08%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.38M USD +8.18%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 41.3M USD -4.91%
Operating Lease, Liability 45.5M USD -14.3%
Depreciation 10.8M USD +50.5%
Payments to Acquire Property, Plant, and Equipment 2.22M USD -70.6%
Lessee, Operating Lease, Liability, to be Paid 52.5M USD -15.6%
Property, Plant and Equipment, Gross 146M USD +22.5%
Operating Lease, Liability, Current 4.08M USD -67.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.99M USD -23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 1.62M USD -0.8%
Operating Lease, Payments 2.72M USD +10%
Amortization of Intangible Assets 4.19M USD -14.4%
Depreciation, Depletion and Amortization 3.37M USD +51.1%
Deferred Tax Assets, Net of Valuation Allowance 28M USD -6.7%
Interest Expense 2.08M USD +16.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%